Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.140
+0.010 (0.32%)
At close: Jun 2, 2026, 4:00 PM EDT
3.130
-0.010 (-0.32%)
After-hours: Jun 2, 2026, 7:49 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 294 employees as of December 31, 2025. The number of employees decreased by 10 or -3.29% compared to the previous year.
Employees
294
Change (1Y)
-10
Growth (1Y)
-3.29%
Revenue / Employee
$1,422,599
Profits / Employee
-$25,248
Market Cap
808.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 294 | -10 | -3.29% |
| Dec 31, 2024 | 304 | 64 | 26.67% |
| Dec 31, 2023 | 240 | 41 | 20.60% |
| Dec 31, 2022 | 199 | -19 | -8.72% |
| Dec 31, 2021 | 218 | -261 | -54.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,526 |
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Alvotech | 1,279 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Xeris Biopharma Holdings | 435 |
| Collegium Pharmaceutical | 423 |
ESPR News
- 4 days ago - Esperion Therapeutics Proxy statement: Proxy filing - Filings
- 5 days ago - Esperion Therapeutics Transcript: AGM 2026 - Transcripts
- 7 days ago - Esperion presents new data from CLEAR Outcomes, CLEAR Phase 2 study - TheFly
- 7 days ago - Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 - GlobeNewsWire
- 19 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - GlobeNewsWire
- 25 days ago - Esperion Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Esperion downgraded to Hold from Buy at Needham - TheFly